Tang XM - Search Results

1

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Johnson FM, et al. Among authors: tang xm. J Clin Oncol. 2010 Oct 20;28(30):4609-15. doi: 10.1200/JCO.2010.30.5474. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855820 Free PMC article. Clinical Trial.

2

Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.

Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Tang X, et al. J Natl Cancer Inst. 2000 Sep 20;92(18):1511-6. doi: 10.1093/jnci/92.18.1511. J Natl Cancer Inst. 2000. PMID: 10995806

3

Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.

Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Soria JC, et al. Clin Cancer Res. 2003 May;9(5):1785-91. Clin Cancer Res. 2003. PMID: 12738735

4

Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.

Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Ren H, et al. J Clin Oncol. 2004 Aug 15;22(16):3230-7. doi: 10.1200/JCO.2004.02.080. J Clin Oncol. 2004. PMID: 15310766

5

Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.

Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR. Lu C, et al. J Clin Oncol. 2004 Nov 15;22(22):4575-83. doi: 10.1200/JCO.2004.01.091. J Clin Oncol. 2004. PMID: 15542809

6

Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.

Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L. Tang X, et al. Mol Cancer Res. 2004 Dec;2(12):685-91. Mol Cancer Res. 2004. PMID: 15634757

7

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. Tang X, et al. Cancer Res. 2005 Sep 1;65(17):7568-72. doi: 10.1158/0008-5472.CAN-05-1705. Cancer Res. 2005. PMID: 16140919

8

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. Fujimoto N, et al. Cancer Res. 2005 Dec 15;65(24):11478-85. doi: 10.1158/0008-5472.CAN-05-1977. Cancer Res. 2005. PMID: 16357156

9

Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.

Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Tang X, et al. Cancer. 2006 Dec 1;107(11):2637-46. doi: 10.1002/cncr.22315. Cancer. 2006. PMID: 17078054 Free article.

10

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.

Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Tsao AS, et al. Among authors: tang xm. J Thorac Oncol. 2006 Mar;1(3):231-9. doi: 10.1016/s1556-0864(15)31573-2. J Thorac Oncol. 2006. PMID: 17409862 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

301 results

Search Page

Filters